Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Alternative mechanisms of action have since gained traction in MASH treatment. Madrigal Pharmaceuticals’s Rezdiffra (resmetirom), a small molecule THRB agonist, was the first drug approved by the FDA ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.

Eli Lilly (NYSE:LLY) recently announced its plans to invest $27 billion in four new U.S. manufacturing plants over the next five years, creating thousands of jobs. This move comes at a time when ...

A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landsca ...

Eli Lilly (LLY) has agreed to acquire Organovo Holdings ... has shown a significant reduction in liver fat in a Phase II study on MASH (metabolic dysfunction-associated steatohepatitis ...

In addition, Eli Lilly announced earlier this month that it is paying $630m for South Korea-based biotech OliX Pharmaceuticals’ antisense RNAi oligonucleotide OLX75016 to treat MASH.